** Orthocell jumps as much as 21.1% to A$0.775, highest since May 9, 2019
** Stock logs biggest intraday pct jump since early October
** Biotech firm signs distributorship agreement with Singapore-based Device Technologies Asia for exclusive distribution of its nerve repair device Remplir
** OCC expects first sales of the device in first quarter of 2025
** Around 2.3 mln shares traded, 3.2x the 30-day avg
** Stock up ~87% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。